0001140361-22-040700.txt : 20221109 0001140361-22-040700.hdr.sgml : 20221109 20221109161631 ACCESSION NUMBER: 0001140361-22-040700 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADMA BIOLOGICS, INC. CENTRAL INDEX KEY: 0001368514 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 562590442 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36728 FILM NUMBER: 221372843 BUSINESS ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 BUSINESS PHONE: (201) 478-5552 MAIL ADDRESS: STREET 1: C/O ADMA BIOLOGICS, INC. STREET 2: 465 STATE ROUTE 17 CITY: RAMSEY STATE: NJ ZIP: 07446 FORMER COMPANY: FORMER CONFORMED NAME: R&R ACQUISITION VI, INC DATE OF NAME CHANGE: 20060707 8-K 1 brhc10043955_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2022

ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-36728
56-2590442
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

465 State Route 17, Ramsey, New Jersey
07446
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock
ADMA
Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition

On November 9, 2022, ADMA Biologics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2022 and providing a business update. A copy of the press release is furnished herewith as Exhibit 99.1.*

Item 9.01
Exhibits.

(d)
Exhibits

Exhibit No. Description
99.1 ADMA Biologics, Inc. Press Release, dated November 9, 2022
104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

2
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November 9, 2022
ADMA Biologics, Inc.



By:
/s/ Brian Lenz


Name:
Brian Lenz


Title:
Executive Vice President and
Chief Financial Officer


3
 EX-99.1 2 brhc10043955_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 
 
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
 
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase
 
Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase
 
Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously
 
Gross Profit Growth and Narrowing Net Losses Expected into 2023
 
Conference Call Scheduled for Today at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., November 9, 2022 -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced its third quarter 2022 financial results and provided a business update.
 
“We are pleased to again be raising revenue guidance for full-year 2022; the Company now expects to generate total revenue of approximately $145 million, increased from $130 million as previously provided. We believe that the third quarter revenue growth of 99% year-over-year establishes a strong foundation from which ADMA will continue to generate substantial revenue growth and improve margins as we accelerate towards corporate profitability,” said Adam Grossman, President and Chief Executive Officer of ADMA.

Mr. Grossman continued, “Enabled by this continued revenue growth, we opportunistically undertook several investments during the quarter which we believe will strengthen commercial initiatives, advance growth opportunities and enhance margins moving forward.  Research and development expenditures increased due to accelerated enrollment of the post-marketing clinical study for BIVIGAM. We believe the rapid pace of enrollment and investigator excitement speaks to the reputation ADMA and its products have established in the market.  Additionally, during the quarter, we mobilized a robust medical education and conference symposia strategy which is anticipated to solidify ASCENIV’s growth outlook and further expand the product’s growing customer base to areas not yet penetrated.”

"While we are pleased with our reported gross profit expansion, it is important to note that a substantial portion of BIVIGAM revenues during the third quarter consisted of legacy 2,200-liter scale product, which yields a significantly lower margin compared to the current 4,400-liter batch production scale,” said Brian Lenz, ADMA’s Chief Financial Officer, and General Manager, ADMA BioCenters.  “BIVIGAM inventory at the 2,200-liter scale sold during this quarter was produced during 2021, prior to the Company receiving FDA approval of the 4,400L-liter scale production. Encouragingly, ADMA has been exclusively producing BIVIGAM at the 4,400-liter scale since the second half of 2021. The residual, lower margin inventory produced at the 2,200-liter scale is anticipated to be fully exhausted over the coming quarters and once sold, we believe our profit margins will substantially improve.”

Mr. Grossman concluded, “As we look to 2023, we believe ADMA is well-positioned in its advancement towards profitability.  The immunoglobulin (“IG”) end market remains one of the fastest growing segments in the pharmaceutical sector, and we are proud to have clearly demonstrated ADMA’s staying power within this landscape.  The pieces are in place for ADMA to sustain its best-in-class revenue growth profile and deliver on our longstanding commitment of reaching profitability as rapidly as possible.”

Third Quarter 2022 and Recent Achievements:


 •
Significant Revenue Growth: Achieved third quarter 2022 total revenues of $41.1 million, as compared to $20.7 million during the third quarter of 2021, an increase of $20.4 million, or approximately 99%.


•
Operating Leverage Materializing.  Excluding the impact associated with the sale of lower margin, 2,200-liter scale BIVIGAM, the Company estimates corporate gross margins for the third quarter would have been approximately 2-4% higher compared to reported results, translating to an approximate 26-28% corporate gross margin in a normalized quarter. As the Company has been exclusively producing BIVIGAM at the expanded 4,400-liter scale since the second half of 2021 and considering the record high BIVIGAM product pull-through realized during the third quarter of 2022, ADMA anticipates this lower margin inventory will be fully monetized over the coming periods.  ADMA anticipates further margin enhancements as product throughput transitions throughout the first half of 2023 to exclusively the higher margin 4,400-liter scale product.

o
Accounting for the transient gross margin dynamics amounting to approximately $1.3 million at the midpoint, in addition to approximately $1 million in non-recurring operating expenditures incurred during the quarter, the Company estimates third quarter operating loss would have been approximately $7 million, the equivalent of approximately 50% less than the prior year’s third quarter.


•
Product Mix Continues to Favorably Evolve: ASCENIV’s prescriber and patient base continued to expand during the third quarter, which drove record utilization and pull-through for the product.  These elevated demand trends have sustained into the fourth quarter, and we expect that the product’s rapid growth will continue into 2023 and beyond.


•
Newly Identified Growth Opportunities: Strong reception to ADMA’s medical education and scientific symposia strategy is anticipated to catalyze penetration into additional targeted growth opportunities.  During the third quarter, ADMA expanded educational initiatives on identifying clinical needs in managing respiratory infections in the immunocompromised host, specifically:

o
Case study presentations by nationally recognized clinical experts in areas of transplantation, infectious disease, and immunology at national and regional medical meetings (i.e., Immune Globulin National Society, Infectious Disease Week, and Florida Allergy Asthma & Immunology Society).

o
Full-capacity attendance of symposia discussions of real-world experience of ASCENIV in patients with primary immunodeficiency (“PI”).

o
The ongoing post-marketing clinical studies may provide for label expansion opportunities for both BIVIGAM and ASCENIV to include pediatric-aged PI patients as well as additional publications supporting product safety.


•
Advancing Toward Profitability: The Company maintains and reiterates its previously provided profitability timeline, which is expected no later than the first quarter of 2024, while taking into account current macroeconomic uncertainties.  However, should current demand trends and margin dynamics sustain, accelerated profitability timelines may be achievable.
 

 •
On-Track BioCenters Expansion: The Company’s BioCenters segment has ten plasma collection centers under its corporate umbrella: seven centers are United States Food and Drug Administration (“FDA”)-licensed, two additional centers are operational and collecting plasma presently under FDA licensing preparation and review and one center is in the construction phase. The Company remains on track to have ten BioCenters FDA-licensed by year-end 2023 and, in the same period, forecasts raw material plasma supply self-sufficiency. ADMA anticipates its strong plasma supply position will support its upwardly revised production and revenue forecasts.


•
Ongoing Strategic Review. ADMA continues to evaluate a variety of strategic alternatives through its ongoing engagement with Morgan Stanley. The Company will communicate material developments as required by the U.S. Securities and Exchange Commission (“SEC”). The exploration of value-creating opportunities remains a top corporate priority for ADMA.

2022 & Long-Term Financial Guidance:


 •
2022 Financial Guidance: Enabled by the strong year-to-date execution, ADMA anticipates total 2022 revenues will reach approximately $145 million. ADMA reiterates expectations for continued gross profit expansion and narrowing net losses into 2023.
 

 •
2024-2025 Financial Guidance:  The Company continues to anticipate generating approximately $250 million or more in revenue in 2024, and approximately $300 million or more thereafter. At these revenue levels, and based upon current assumptions, ADMA continues to forecast achieving corporate gross margins in the range of 40-50% and net income margins in the range of 20-30%. These assumptions translate to potential annual gross profit and net income in the range of $100-150 million and $50-100 million, respectively, during the 2024-2025 time period and beyond. 
 
Third Quarter 2022 Financial Results:

Total revenues for the third quarter ended September 30, 2022 were $41.1 million, as compared to $20.7 million during the third quarter of 2021, an increase of $20.4 million, or approximately 99%. The revenue growth for the third quarter of 2022, compared to the third quarter of 2021, was favorably impacted by the continued commercial ramp-up of the Company’s intravenous immune globulin (IVIG) product portfolio and expanding the customer base for BIVIGAM and ASCENIV.

Gross profit for the third quarter of 2022 was $9.7 million, compared to gross profit of $0.4 million for the third quarter of 2021. Gross profit growth during the third quarter was driven by a favorable contribution from ASCENIV.  Partially offsetting the favorably evolving product mix, ADMA sold a material amount of the remaining 2,200-liter scale, lower margin BIVIGAM product during the third quarter of 2022.  Moving forward, this lower margin inventory is anticipated to be exhausted over the coming quarters, after which production throughput and sales recognition is anticipated to be confined exclusively to the higher margin 4,400-liter BIVIGAM product.
 
Consolidated net loss for the quarter ended September 30, 2022 was $14.9 million, or $(0.08) per basic and diluted share, compared to a consolidated net loss of $17.7 million, or $(0.13) per basic and diluted share, for the quarter ended September 30, 2021.
 
Net loss decreased by approximately $2.8 million compared to the third quarter of 2021, primarily attributed to higher gross profit of $9.3 million, partially offset by a $2.3 million increase in interest expense as a result of additional debt principal as well as rising interest rates.  Additional offsets during the third quarter of 2022 included increased plasma center operating expenses of $1.7 million attributed to having nine plasma centers in operation compared to five operating centers during the same period last year, as well as increased general and administrative expenses of $2.2 million resulting from increased headcount, commercialization, and marketing expenditures.
 
As of September 30, 2022, ADMA had working capital of approximately $179.7 million, primarily consisting of $162.9 million of inventory, $34.9 million of cash and cash equivalents and net accounts receivable of $20.9 million, partially offset by an aggregate of $43.6 million of accounts payable and accrued expenses.

Conference Call Information
To access the conference call on November 9, 2022 at 4:30 PM ET, participants may register for the call here to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event starting (although you may register and dial in at any time during the call). A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ASCENIV™
 
ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). ASCENIV was approved by the FDA in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and adolescents (12 to 17 years of age). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886. Certain data and other information about ASCENIV™ or ADMA Biologics and its products can be found on the Company’s website at www.admabiologics.com.
 
About BIVIGAM®
 
BIVIGAM (immune globulin intravenous, human – 10% liquid) is a plasma-derived, polyclonal, intravenous immune globulin (IVIG). BIVIGAM was approved by the FDA in May 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), including, but not limited to the following group of genetic disorders: X-linked and congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiency. BIVIGAM contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin antibodies. Certain data and other information about BIVIGAM® or ADMA Biologics and its products can be found on the Company’s website at www.admabiologics.com.
 
About ADMA BioCenters
 
ADMA BioCenters operates FDA-licensed facilities specializing in the collection of human plasma used to make special medications for the treatment and prevention of diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional, and pleasant donation environment. ADMA BioCenters strictly follows FDA regulations and guidance and enforces cGMP (current good manufacturing practices) in all of its facilities. For more information about ADMA BioCenters, please visit www.admabiocenters.com.

About ADMA Biologics, Inc. (ADMA)
 
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789, among others, related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
 
Forward-Looking Statements
 
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc., and its subsidiaries (collectively, “our”, “ADMA” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” “would,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations and pro forma results; the success of BIVIGAM® and ASCENIV™ in future periods, including certain opportunities for such products; the production scale of BIVIGAM; future growth opportunities; the timeline associated with profitability; the ability to obtain FDA approval of its plasma collection centers and the associated timing in connection therewith; expectations regarding the Company’s future gross margins; and the ability to achieve source plasma self-sufficiency and the associated timing in connection therewith, as well as benefits thereof. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

   
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
   
2022
    
2021
    
2022
    
2021
  
                         
REVENUES:
                        
Product revenue
  
$
41,054,429
    
$
20,644,842
    
$
103,991,112
    
$
54,452,633
  
License revenue
    
35,708
      
35,708
      
107,125
      
107,125
  
Total revenues
    
41,090,137
      
20,680,550
      
104,098,237
      
54,559,758
  
Cost of product revenue
    
31,433,496
      
20,295,213
      
83,010,156
      
56,897,959
  
Gross profit (loss)
    
9,656,641
      
385,337
      
21,088,081
      
(2,338,201
)
                                 
OPERATING EXPENSES:
                                
Research and development
    
1,041,947
      
770,557
      
2,539,444
      
2,917,072
  
Plasma center operating expenses
    
4,859,450
      
3,146,221
      
12,755,525
      
8,191,890
  
Amortization of intangible assets
    
178,838
      
178,838
      
536,514
      
536,514
  
Selling, general and administrative
    
12,893,139
      
10,726,797
      
38,563,136
      
31,198,880
  
Total operating expenses
    
18,973,374
      
14,822,413
      
54,394,619
      
42,844,356
  
                                 
LOSS FROM OPERATIONS
    
(9,316,733
)
    
(14,437,076
)
    
(33,306,538
)
    
(45,182,557
)
                                 
OTHER INCOME (EXPENSE):
                                
Interest income
    
7,236
      
4,256
      
42,573
      
32,241
  
Interest expense
    
(5,580,366
)
    
(3,298,680
)
    
(13,542,419
)
    
(9,741,110
)
Loss on extinguishment of debt
    
-
      
-
      
(6,669,941
)
    
-
  
Other expense
    
(9,641
)
    
18,546
      
(195,942
)
    
(106,772
)
Other expense, net
    
(5,582,771
)
    
(3,275,878
)
    
(20,365,729
)
    
(9,815,641
)
                                 
NET LOSS
  
$
(14,899,504
)
  
$
(17,712,954
)
  
$
(53,672,267
)
  
$
(54,998,198
)
                                 
BASIC AND DILUTED LOSS PER COMMON SHARE
  
$
(0.08
)
  
$
(0.13
)
  
$
(0.27
)
  
$
(0.44
)
                                 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
                                
Basic and Diluted
    
196,383,935
      
133,770,147
      
196,204,893
      
125,682,400
  

ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

     
September 30,
2022
      
December 31,
2021
   
ASSETS
  
(Unaudited)
        
Current assets:
            
Cash and cash equivalents
  
$
34,906,020
    
$
51,089,118
  
Accounts receivable, net
    
20,902,385
      
28,576,857
  
Inventories
    
162,913,633
      
124,724,091
  
Prepaid expenses and other current assets
    
5,372,484
      
4,339,245
  
Total current assets
    
224,094,522
      
208,729,311
  
Property and equipment, net
    
56,946,090
      
50,935,074
  
Intangible assets, net
    
1,192,254
      
1,728,768
  
Goodwill
    
3,529,509
      
3,529,509
  
Right to use assets
    
10,335,873
      
7,262,658
  
Deposits and other assets
    
4,459,322
      
4,067,404
  
TOTAL ASSETS
  
$
300,557,570
    
$
276,252,724
  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
                
Current liabilities:
                
Accounts payable
  
$
25,197,806
    
$
12,429,409
  
Accrued expenses and other current liabilities
    
18,378,932
      
17,214,988
  
Current portion of deferred revenue
    
142,834
      
142,834
  
Current portion of lease obligations
    
720,755
      
591,084
  
Total current liabilities
    
44,440,327
      
30,378,315
  
Senior notes payable, net of discount
    
141,365,706
      
94,866,239
  
Deferred revenue, net of current portion
    
1,868,739
      
1,975,865
  
End of term fee
    
1,500,000
      
-
  
Lease obligations, net of current portion
    
10,636,083
      
7,462,388
  
Other non-current liabilities
    
362,179
      
397,351
  
TOTAL LIABILITIES
    
200,173,034
      
135,080,158
  
                 
COMMITMENTS AND CONTINGENCIES
                
                 
STOCKHOLDERS' EQUITY
                
Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding
    
-
      
-
  

               
Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 196,776,871 and 195,813,817 shares issued and outstanding
    
19,678
      
19,581
  
Additional paid-in capital
    
566,149,846
      
553,265,706
  
Accumulated deficit
    
(465,784,988
)
    
(412,112,721
)
TOTAL STOCKHOLDERS' EQUITY
    
100,384,536
      
141,172,566
  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  
$
300,557,570
    
$
276,252,724
  


EX-101.SCH 3 adma-20221109.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 adma-20221109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 adma-20221109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image0.jpg begin 644 image0.jpg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image00001.jpg begin 644 image00001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2022
Entity File Number 001-36728
Entity Registrant Name ADMA BIOLOGICS, INC.
Entity Central Index Key 0001368514
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2590442
Entity Address, Address Line One 465 State Route 17
Entity Address, City or Town Ramsey
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07446
City Area Code 201
Local Phone Number 478-5552
Title of 12(b) Security Common Stock
Trading Symbol ADMA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 9 brhc10043955_8k_htm.xml IDEA: XBRL DOCUMENT 0001368514 2022-11-09 2022-11-09 false 0001368514 8-K 2022-11-09 ADMA BIOLOGICS, INC. DE 001-36728 56-2590442 465 State Route 17 Ramsey NJ 07446 201 478-5552 false false false false Common Stock ADMA NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://admabiologics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10043955_8k.htm adma-20221109.xsd adma-20221109_lab.xml adma-20221109_pre.xml brhc10043955_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10043955_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10043955_8k.htm" ] }, "labelLink": { "local": [ "adma-20221109_lab.xml" ] }, "presentationLink": { "local": [ "adma-20221109_pre.xml" ] }, "schema": { "local": [ "adma-20221109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adma", "nsuri": "http://admabiologics.com/20221109", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10043955_8k.htm", "contextRef": "c20221109to20221109", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://admabiologics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10043955_8k.htm", "contextRef": "c20221109to20221109", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://admabiologics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001140361-22-040700-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-040700-xbrl.zip M4$L#!!0 ( ^":55,G9("2@, $D/ 1 861M82TR,#(R,3$P.2YX M1C")(=+PBG/")(!XGDXB2:3.(YF6A7% M.6;JCHO\!J>PI&KA_2HA)2G!B0=T&DS.U[+A>GY^#IZG 1>9)HGB\/O'AR\V MNL.:8$=%KN"4L)\=\O524$<_#8UY"25NE.S@:S'Q;#8+K;6!:B)R@)HPJ2!# MN(U/5./0!I^'E=%!]0:J38&W54FA7%JPL]@\'5P*M0_?F#H."29='1*C(.._ M0VWH I7H,7?RU.;0F(U/Y$>Q/XD]W3( F*:!C'$%E6Y0NU0O%@5A*:]7])JI MZ-SMPA-.@:WQW+ N/$GR@IH"VK65P.G",UONNUW^40@<:*D.(CC%![;$F$/M M(G5'6F4/V\". @JTP[+3 YJ$%U@HH@N[;:'PGZ5%X7)H6MH%T_^;C^'YJC, M9O#MZ?[ ,;22;C@JS>%_QY);IHC:W.NM%[FMO =(LO .(IKH+GZ"4\*([:A( MWPU1!'S@&-I#R!)0T8$6WV78)^GSEQ(GC^S*COM=4GO7D$.>"%)4TA,W3S$:(P&NT&B*@P=O1B, ,Z@MD2.2M0S4<$5L2-"2R@YO!L*C]"WQ6W98, M9^:)]G+XOAL5HN/E&QX_GOCQV_$ZU& -ZI3XW7*J0@PJO\/;T;@-:+_5CDG< MNIB9[_Q,^E.3_C0^6<59*,Q7^T@!%FW"GOG1A:]?[X.JOO/N/#*J_U.N+K8FG&'KOZ::3U(>7C=4$A@XJ+S9V>'W\$VBRW6Y)33D3[V3ZH1@Y? MU<<\^@>59N_OPJG1QV[/2S\6>\7\S=/.Y5:(?1Q59%=_ %!+ P04 " / M@FE5QRLM,H ( !U6 %0 &%D;6$M,C R,C$Q,#E?;&%B+GAM;,V<76_; M-A2&[P?L/W#>S0;4=BQCPQ(T+K(L+8*E29"DV!>&0I9I1Y@L!I3<./]^I"3: M(GE(*14EZZ9U>-[S\NLYDJQ$>OMNNX[0%TR3D,2G@\GH:(!P')!%&*].!YMD MZ"=!& [>S;[]YNUWP^$''&/JIWB!YB_H5TK\!0T7*XQN[VZ68821YXTF1Z/) MZ*>C7XY*\>&0YT=A_-\)_V?N)QBQ?N/D9)N$IX/'-'TZ&8^?GY]'S],1H:NQ M=W0T&?_Y\>H^>,1K?QC&2>K' 1X@IC])LL8K$OAI-NA2^G9.(V$P'>_Z,BKX M3T,A&_*FX<0;3B>C;;(8%$/DX1J="/E6TQ=SFAP?'X^SZ$[*C$*+]6[:;/40 MRM>/D@C?X27B_W^ZNS1F'X^Y8ASC],J?XXAUF:6G+T_X=)"$ZZ<(B[9'BI>P M3T3ISH:OSC%?G/5>NF^:"O72VM;953GN8)5+W30?]"VF(5E)G$4+UZ23,-7-,<#!:D2_C M!0Z9L^?Q#T/^(9L%^^'S.6'GS[-YDE(_2(53-HG3 1A+PY2/78F-Y8'R?&FH M%"=D0P.L]*"-X',TCUZU2-(>YT,SF:XCUBV_,L#Q\-/] (4+DW:6-:%_1.._ M;\?[4>LS/:/ROO@T$$-B'RNF42C& 6$GRZ=T*,UH2D_5Z$X?YQ7:BT%-,R:!KP!SJZ M%F M;B+2G#,K0DB.'991^ZZ1FHLL4PO*!;X6K_8YOB=1&(0I^T+[D5UPT-"/%*3, M@F**D* !OKJ=*W:-SB9P#0FS?3L2@<,B:]DC4F=595AUK2#5Y-(^IK<4\_K M; FR(SV_V*4WRR6F"D+5PF*R-F$#?,VVKC"N[,&$LOPR\.4> 7^7:>0%<)LD&T]IE8)3#Q0#(W96$9MY289CZJ5D><+I> M)+FNO[5BWGJX8JS;8ZT;+=-0/88>VJ^A,];[@H_@?>2O%%#!6#%=)=:@%"0G M5]Q#IB;(=>ULUX1XVV'9A7>!5"R>3*4D$P@"N=W=B'@?)H$?_85]^IZUJ-\2 M*U3*[0E-Y>!.A>+I^J8%;%]U_P+*VM_*R*.(AU$6[\=]#=,>DMH+#M_M4!+4 M&Q^@7]=\YW?8JPD'="#CDLX9Y277=CC7.ZA'NIJGL9X+^D<[M)\@[X:EMQ%? M2H&9USR[HW[W"['?V'=A _&@1J%=T3@@77)T33ED7D6XGK.GN\":!1&/]H-L M>-](S66&B9;D*LV 5_LD7\1LI"]W>!7R7]#$Z;6_5K&R28IIPI(&&$.&KBBV M>)L@-J;,\@C:AQ"/'99@ZX:1>@LL\PNI!;YFIZ[H/6?%0_WHDGV9W/Z.7T!\ M#1J)7TW3&&#%T2W!L+D=82A',%S$4!9$+-H'BDW[1FHN,\2Q(I=!!KVZ(OE] M&.'KS7JNW2"5=Z,\O8^4 IL#*E>3(C-O5+& M4G7HBL@'?WNY8"41+HO?2EKPK-!*K!JUC<$U.+NEV-Z)'6E;KN";:9 LZA'M M5?M,7KD=4!T8TN2BL'IW52&7<4#H$Z'9 .Y3=NU^3C;L'/)R3A;PI72M#*E: M*C(:UXS5WVWEU.G*7C_5#J**).4;E&D1H:C0(Y[0AX*J!P3YJAV#BLN:+)=8 MC7ZZ*K2+-::K,%Y]H.0Y?3PGZR<_AB_VK4JIL S*Q@4%^KHM)%L7]@(R9XK" M$0J42U"AZ4.MV/>6O&H3H-H D^2:L/AV50MGBP5C,"G^NPIC/ $KP:*3Z@#4 M-:X"P-5M#9@[L%> *4_P7P3>B ^(2]!-W(NSA6U/R2N6'Z(?2)'9-WH>CGRO M)OE>3?*]5LCWVB;?^TKRO1KD/SR3?I+OU27?>SWY7A7YWJ')G]8D?UJ3_&DK MY$_;)G_ZE>1/ZY#/-JRG1_UI7?:GKV=_6L7^]"#LG[./-_2!/,>9Q_*^:*'I$.["+$.;SD%LKW"2#CJE_'A&=?L6_H M+25?PE@#KHX48EV3N@)>,6Z%>KB/6NA#J1K_N]M"0M:C(C#M,50)EKVPE(.2 M!=8$Z-SUH3^_[60][LL2\* O),Z.^+EA.X=[R;O>L;Z4HA_H\V"/\%9W##S MZRML.[H7MW;!0WO9J6-\;TF2^M'?X9/QMP(V(82R(G0%M&3;"M90#[7@UA,U MQ',)8IK>W-RW[BL$O'$'+-A+.2#\@&O[)< OILXH]@'HH5 Q03G4Y*T/)2-G M+WW0/8WO?%"EL^Q2FS?U@$YP XA]X60"RZK=VQZTS/8IXR^ZBFX?20S_[8PI M7$Q&#S<@3C5S19W!UT0>*)]EK2AK[L5?$Q@WAE0OIDRBJA0TP@X=/%&/@PUE ME3#QY@]\H HIIG Q*3WD@^RSXBLD03[X?YCTB(#OPD MO6EW2/6*REBJRMTS]*!#^UA>DP?J\Q<7WK^LYR0"'H&T*(JI@8H&? )^KA U M6YLH-67,K@DJ(B@/]>!!2=M>D5J+*],*B 6P1I_VF94Z5O@!8\6DE%@#0B4G M5VQ"IB8J=>U,AO&P',*[0"H63V9/D@GJ@-SN3MT7V^"1;08&'HBQ2913N"QQ M5:=S+64F(DB$>O! C'7#2+T%AL_L9;5Z=M>=BG!0 _#X !4 !A9&UA M+3(P,C(Q,3 Y7W!R92YX;6S56UUSXC84?>],_X-+G\$8NMLE$W8GS28[3-DD MDZ33CY>.L 5H:EN,;!+X]Y6,E"!9DLV2[-R\\.%[='6/SO'7Q9Q^VF1I\(!9 M06@^[D2]?B? >4P3DB_&G771145,2.?3QQ]_./VIV_V"<\Q0B9-@M@U^8Q0E MC"0+'-S<7L])BH/!H!?U>U'O7?]#?R_>[8KQ*;@HP[ MR[)E"B/<2?@^).BVCBE,2JK MHO>&;V8L50F&X=-<3H3XUE6PKMC4C0;=8=3;%$E'EBC"+291\$T-+SE%H]$H MK*)/4)Z(>%(_T>:K%P2[]6,TQ;=X'HCW/VXGSM&C4"#"')=3-,,IG[(:7FY7 M>-PI2+9*L=JV9'ANSY,R]I1&K,Y(K$[T7JS.S\^9PV/*6P@WW=,2I2]39Y6O M7FMMFN.+OGJII?65?/62J\SWT:C3%I)EZB&]RGTESYA>,6*QRL0_:C+6 M3]D2$:X0X_FZ\9*D3PZ8,YJY5I)Z2]\O[R30,@0E#?21E"68C3M]<2G'!\XQ M8W(W\]1=%9WN[XNO*> 9KS81%5^F:&$H:(W)=3!B\#3T%=\@HC%4JA@!5E'9 M[NF\^9D?T!W[HQ5C[)@&!IZZ;C^\ZWSK61TM1WX$7]18OB""2EU+4G>4S9BK**WQVGB<_IFI/9GM/$OI>W&J$YH6$$5%\<0K252QH22L]\ M .^9>[29))PMF9/=#RN>DWT#5O.)$PO5(>W(M?*&,Y5TQ0B\*\Z2A!,MY-N4 MY#BR.L*#T]Q@Q4%U0C.I5BZPIE']'(\#.L1Z$% 0X,K;J1RT^ZL,2FGX[4%9^0TM2I3^0U;.]H$/ M:%/= +7WD?K$ <8>90/('AJ=J X4&5>NCE:J0>V[W#(D'[^^VV8RFAJ36F%P,(P9/3%_Q#4H:0]63 M,I#[9E=4*]KRD)L'(5?%BH G;#.1!GFM"93(D#MCZ@ASL8F7*%]@RP_H/HAQ M)-8A\'1N0:7E$5G/H)2&WP"[R#!;<)]^8?2Q7)[3;(5R^\VO%ZG=#3F0\.1O M3ZS5_9 CD3(#Y*;8G]S#)3%RG1P8>-*W(=,@NB.%DAMR MQ^N.IB0F)??J5U1B1I!Y6>8&J".\!0!/Y48:34=WRWBE+^0^UPW#PI8XCW'U M#PKQEQUV/9_7[I.;@7*A?$!XNK>FU:"_+X_R >0^EU'_I"C6F+5V@Q-N]X0% M#MX9310/\XL0V-U\L*R:I#&6-?L^R:;UZ@:3-?5U01B M 'C^^X?!YWGU;'7]>=5.EI H]>-D1+(@CJ G75547='T6B=*RFFC(WAOW\;? M[NU',Q7540RM[&>2*K>$C*M^?))Z$IBB0 Q=#U*$H;32(2T'1U?5G4J)P&='55*&A6S,;) MFII0TJC*IW2XNJHH:?::9,ND@(]-,F2)DLW&/%V-8RCNB.)BU6B*7E&;L!&I M&HD7+XC#^!:0T*;Q2 ZB::I;5%_/CT(PM'K__5\('0TY8?()GK,@"WGOJ)/_ M%A__IBCHA]7@TL_"#G2];:FMK6VJ3IJK8/3>#Q+@MMAA@!T M$RE(3++>7E%*2$<\(TA,6>%_3H)OQZW3.,I@;.4&L-E"-'\[;F5\FG4D"E ' MVAYU"AS HQ>S&4JS6P\R1]E;?D( M%2X [TE 441&HBD/NB= "":(\3$DMRTYTD="LW]3@G6;8,?0.,;<=1W']5S' M=!DCK M(3R/8.G-3@'$A(3]B/'IKWQ6A]2S"6T! M'33#(PX3X7THBGO2.AP+JI5$W0-9(*K3M,Q"B"#96R__8T9:VB M6/#P<2L-1N,0$''4:?:1#U2J156.K4.* #[".Y6$BUI.09+TZ@M& 9E+\I7IQE\0CX M=CQ%:1P&#'DAL&95GL7C+L*+A4,NY)#D]NFW&X(!!&G&DT,T(LEM M$"E"3G01F61Q]2G)1Y'?<@D%$\KG)L6X;N49\PLH'T=I1?E\7VCXM_=1W^@3L&YQ-J6 M)B>#WI41M!@*$!1&9LH,YJ> [=R[B+_QD0>FD'L@?8=E^9&3Y =>"&O%>.YS MK)V,CN4*>L!<'_#;(!6!BNP"2FI$9D35./.QJAL,ZSKV=-_UL.[X5'>9JML; MR/N3LR\GZ$/_\O/EI_[I]0'J7YRVUQ%0HK*)Q(8E6)IO>MUZN\$L?(]QY!\?*P_?1>P;"A>U/>590[$"N4U M)+?>GGJ Q'_[-1"*=;ESTC_ I?T(1/BXD.+7&0C,TSP\=QJS.M-JOL,\VV$8 M?K 'DEFEGD&X;ND&\?Q-C+2Z9!8Q3N$&9GR5YEA^9Y*N6KZ M>*,PB*88EJT[3TV#'X!U;LBT7P1%J&2?)8)@4U.QY7/58CJFF@Z:3MWIZ[$GY)$SY&$SX!/T!%GS* M@MS&![46U&79_A-)B&>8YFD\&@5I*F8E^!SEZ^HO3>C[TJT_N$;GHW$8SX!J M39Y!%W'[X9DM+=O\5P3II=E1BX&]F2AUPF/W]]77*-$S!1#%5IA&+NEB8)^8&+F,/6R;*1WXCJZ;.G8)9@#V!OLHO0$9I7SV6*CDW"Z3 M*S"U KEW/K?J+)MPU;5L@WH8N[;GJ"JCFF=A\,U4W]V%52=H_S\\60'_5@(- M&$/X<\,%XQ_VR6>YC+?UWR*=4]S M=,?QL0V+!*NNP>@FAJ6-L?423)C[R/4,JK# M#!7Q@EP8S F(>)33B=9\$TX MYZ 8>;J=KG\4:SS9FG\&),(*16*)[M1P6 6CU,FO+*J7XV@>??OEG:-K]F$* MQD;(Q\,XXBB2!N6!,)C#B;![$'C=!-81@P[VULH*H=U.H.*B=+ M0_.([;M< MQZK!"7B>!'N,).])&P[BFF:*P+"6T6"'XBA/FKI_.Q1S(]@:X 'D8O$4>3R,[P1N1*' ('*47Y$?A(+O@Q2$0,8C)I.X &VC29B1B,>3 M-)RA%%RTU)_)ED6#V ,X2>EQBX):,%GN 2$2S@5/L10#7)@P,G;;V=(V*_^_+60:6< M-G10=^*5/NQZ(@K\D^9I9Y^!Q#<"N-:"X3]Y<1QZ!-@F ^9M]7YY-]5!=1UN8CJO,IY7&'7KR9)+]U5D>7H:%*@& MA-5QC<:U[?S!!)@#ZV8A9Q:V\<7N_9YFH]./ Z0;:ALJKK /UQBY*QR*_'?! M3MQ"ALLO022B75VDY"N^H4OEIS<1\Y.+F.L8-!BLX.CV"VAL4-MA3;X0QC7' MM V-VCXV;==Q=-7E%C;%SAMW-G"\W^1+08 YGH$+LMO.:;P+F3<"\= %SE7!AOXAL$/6C0:9HJ^Y^UO)G;RNF^"YTWPO#+! MTT_3"4]6BQ^J$D9<;%'?][!N@,C!ML5\1^6VBJF_00CQ3?P\6OP87,%[=#/Q M4]1]!O'SC+&SFA.9![-XPED#454BN93317 +D+--,*DI-@WKF43DSY?S8!CM ME?DN4D(6@)7[8R):7GPJ0HIR>[8^ 0':,^_6WHB#MGDR/AWFFF37V4RO"!D) MD5M4U[.1%X=[6^Z-+B^-UXV-BR*%6ZX,7LII$$UWPP"^K)3+.P=B+B6?/N'P M85[.;LQ3+*KR8IMJ?84R.V.YQG=,S"B4TDS3/2D.ZM:281$+:P0S2K%G M4\]E*F7<8UAS,?8W22L5AADLFNLLIE^_1[KU,OW6I,8L$/&!6B\WSZ:08KD0 MJV^>$\,79YY\7W6PZFNN"Q:OH3$3.R[%&Z6OB<,P3YZN_;#<_+'9L#2)%\XR MF8:C:Y;JZ,32,=.HPPU-MU1#9\PP_4UR^Y8<%R'4J]PYDC+R)_H4QN#*H"\D M^-^$.5'J9IO^>:5:JXX@#H_=VJ@O5_>:99] M*#>PRLJ!/)(U%D>R4)R4%,N=-]U3] W/M%9]"T=NWJ[6>_OENS,[IO[Y&DH^ MD"]9-OLD6YWFC>K[PIQBC3NVHUDN]BWL6 1ST[8OX6)'SV'S[FZ(4UY@)Z/-DU0%/>?8>GM_K[]^_G]]2]IIV+Q[GRUO&VGV+ MG=S\T<_X".EM5=_8K5D?IU_&T7T^R$[ AX4Q"3-Y,N 2M$L1K@?E4+M.[S0& M=28*GNO$W$Y%\DJ#XU(< 6Q>Q7& \OL=RDL,#^3M@6![IQ/0C@04I3A!D8"V M)J"A210!IU*9S0KHFRO9I$"HT-%":V;#A',DKP,!52\5^C4'NU<.;:CYV +A M)D"'7;6OM?SS%_0IO N(! >&VQ5F#UR@@BL63MI_%NW\Y>U.O>4GK>MO< MV:)N]?;8_HM?N_.%^L.LT_O'?QJ3O+*4GVT#=]'4K?//CC)79$^;WR-6JLN+ MN%UA9^,D#'?+P(:'R@.P9R4A^*\:> )X)*TY:5\(*Z\L;TI&X(AFQXJJYU0)S]UEQWUL. M/4*;_ /= -*"J+I(7L2I*R^JB@Y79\;2(0E#&1SS.&*V'N M C#!TXGW!PPK0FBB?1@0+PCS$24,)$-I#M8!S"@IYA;4IS:_3@9>O!FJ+F66 MP?UH5AZ)6WL:I8CIUV+DYO?!N>O[.;./R9I%OBS5=&1QZ1_ MUO8.\AV./R=!(C-!TXVE[XJM$38!D43)1/ZU!Z$5\F/58AB0F"G,! KB_/Y( MCX,P]878@H[*I2M)5=03(9%)!$UEK^"H#.,$)L$VE%WW8.SE>*T_4D:EJ:[) M_=@T,>.QVF;91-TBA:6Z%L6H2/ ]YK#*('_JM+E["+;5K2\;H_#!7E_(A!;2 MFK[3LOXPZSYN)>OWDF''67"/G5TG[: /20!2^#./_O-:EOJF*^,O=&I^+RD* MSL=V"ZX)-UYUC=2S\,G;*GHYJTAF(;_*971>7:_VOP$XSB(8)O^:D=QESXSB2[_<7\?X'KJ=[MBH"4O.4Q+IB M5;:KVF]=ML=V3^]\I$A(8A=%:DC*;G?L'_\R ?"2Y*ML682,FJDN6P<()/*7 M%S(3'Z;Y+/KT?_^/IGV84B]@/\'/>9A']-.'7_B_XL7_Z'2TX]"G<48#+4_> M:9_3Q O2,)A0[4L8>[$?>I%VD42+/$SBC&C'Q_O\J^S/0>(O9C3.-3^E7@Y# M++(PGM0'.3L_'8<1U4RS:^A=H^OH [TVP'XROTG#R337#-=UM(YFZJ99_WZG MPU?RBUC*AU$2W&BCB9]$2?IQ[V]C]F=/R_*;B'[<&R=QWAE[LS"Z>:?]YV4X MHYEV0J^U\V3FQ?_Y7F/O9^%?])UFZ//\O9;3/_..%X63^)T6T3&\PD9^I_U- M9W_>[_'GXQ<;#ZD-LO<)YHCVC\[UM!YXYI[&]^?CGF/!EJ7^Q[UPYDVHWOUC/H%//\/\/E6PN&^ZSTMW]J!W M6IC#4_SU>S$\^#;4/H?PV$GH9]HPCH$7?1C]:%P?:69I/\3E.J_60;74/[%D81"$RB><"_/VO_ZB2=?VE',8K)C+X(-S]YC5]3 M^(I8Z-PD?/NK*L=7FYCFMJ'47J'6'N @N 6S&-G _KK+O/F8>,M:8SSX;>+ MPW\1[:3[_[J,H3Z?[@^U\^'EZ0G1OD1>%]Y*KNAL!&K#)0QTPH:ZS]0"B[6I MC@C*FJ[VYL3+ N_?[]B[;[4W?__;P#3U]_@;^]%XK\%FYU.JB7?VD]G??U0(:P.\Y,Y[! MQHH78\_/%RG@AJ#)]9WF[$H51W)MX8:R-J)8*^9T*B3TI)#8"?+R(HLX-]3B5 MWC,>$)L/MN^U1IE8RW# "8UI"I2!GW-&1CY<,M:\.=#Q3S#Z-S4R[GH;^E,/G&J8% M;!P#@RYH8^G98@1CP1LU DPJS1#.<.Y4>!09KNL:-L;W:<2^7RT_3ZZ]-,C@ M*>D\84//F9[Q1F$4YC>D@&7FA8$V#+P9MS. "PCJT0SH Y( G[D_#>D8U _U M 7_P[-/Q&)S6%$F!B^D^1@W=+62?DVV_I=UR126I U+(G\,8-@Q!?X/[G56? M6*(Z0?HFP%7.DRSOE")7\R.8.4KJ+%\$-TP,?#[ZY]'7X;R#+O>],=K"QZ'R1<\ QE+%OYHC\)%B@C)EZ M\-0*JS@N^R*?>4&A80!4@$%PH\F:O60L,4L01W\QP9XF(-IS;<;44:2!=>/S M67A,DY7F3W8S T*%3$ (2)'"+)$^<_R5[0M?>>-;;(-@O@EPF3:"/6;;B[L- M\C@'R99KP B431&YAHF)=F)\[_NFZKI.F2$0=&-$(%7)LS.YO*/DR?C MJB-'VH-,A8_!#B A@ 1"%7@-68P?P2T%AA>L7 B*!MR;N@/V/@.94=]3^'Y$ M)YY_HYG$U/4.R&+X8 9\4^X6$6QQ$](H8/H$B!2"S(6I@.B)DFOX!@#J.)P7$-[&E-!? Y#4%,'M/X+Z(51AOC&"[\J["" M$/[H%'$OO 3QX0?((B@:UR"L\?41JC.(K LKNBW+" +[$HK%BK6%A]/\3"0,36 MU35\**/ , &,'(UQ8KB:KG;)!!NHXX47D>;FEW2L"'$K'9LR!JD#AAO:9C>P M@*FW0"[5T*#A;)3,.%'B%7@;Q%XQ-*@I+\L^[GT^/_MR!OS[&63@]R'\9^\6 M:WP.'^J,\%,=;YQC\-:+KKV;[):AZL/<%HX6(_/YL?BSIF,,F@4_<:+ZST6H MN"-> SP5X6KSD>'J.I56XJ8O:HT!9(*:-39D9BS39"*VT6 R!K@0/P.^!*I0 MA"57WZC?A67$+(+"[&T8NX4<0BR%L]DB3B81Z&RP4DI/]>AKX8JB&RHL @#> M#'R,BB6G%< -4.5RLU!8L$L,BLPN89L3 MH5<[ [7!U6]3%@.@;O!)&1 M,6JB;0&@]P0)1["2#B"$\?&RX\%H"3($'E)1(H"]07&!.A%D0 0>#P(^8.8% MF+!A7AB(@ 5_RN9=WQ-T79CQ%[$?85>S$"SR-AL<:V,M:X+PN,7G%,-3VA!6 M#L1DC/'NF=:$YBNP"V A [L9"/MQ3]]CO\^]("A^_]$SN8;DN?^ KI!\!Q=G M7X[!UKG$R>UI8?!Q[Z^^W[>IZ;E^S_#L4=\C _#%S[X!7B M[RV-MH:'MAQXO*@LU2I^SX3(.^UA$48!F&#)DD9<+2\>_S0B11E*&WX$5$:' MO*QA(_]DZMU^&16ZU7 7UA>+2A:N,!L1AB](E'ATI[C.>/^6!^ J+#,D=X;C/ICP_;A9]/RE:C8-5%Q.L=H$L+O MF$70)A3<2, >. SA7_!R]V'R0M@[A^B$!068P=WP_'R=O &3,"/S8LP 7.[ MT#]"O[SF6Y$U+I1PZ4C#K\2P%(*_'FCEX8;"'1J+@X^FA+E.%E' #3_F13;E MB-FQ?]:F0"\61*C$5QG1$$<,,)?4B[.($Q+C.(V1UE' ['7,P<^WS!8-10_< M%#!<>7!+3+>K#;/&LA_G_?*(% QWBQM\F_=;!- P&%U*:O#DP1]BU"F?(YQU M;8Z'#?D4[.K)=-WB09#S==TC^4U21! +ESD3AO9Z_YNYO*5##?8[S=ECEAUJ MX/DP">("(Z'*WHHQW($W9"N>+G.\_\X>RXN5DP:D^#M-L+0AJ M)+:0:>I[B%\4C">. MQ_X@>(K&DGBS@79Q\C286/7JHX1.;)F83!/PC@G3%Z*XX)U7RV_")^+D[@#LFN1,LF3E.IO M^=P%([C!*FS7G4.L5T1+ JU\4(0KOUOO_-2OC%LFN/^]"*\ \MR1;W[6T7^& M_9Z(>+# *QZ(EB&+QERZRB9^C(31^ZX]=@RO%U#3IHX_\ W7&>N^&\!_ MP$96-O&NV<1G0K]_"_\$7/,#:7:Z^<6[ F-M!*@[O$JB*_KN@>DZ2Z>&ZXR! M.8@=/PTQ%8CEJX"L0+BS@\'J4)Q9">Q8\3;+J3BU"EA^@C#2%CD>DE:'H77[ MK!3.A3E1A2[AT32B5\Q,#^B,G6:F("3%":X(7!:I<,S62=!RJN8BHJP\N:1, M[5B__N81*3^0%I'/9IY&F7C'AA_1&[!7E;O_(Z*M1WNT/PA\>^PYMNW3P$X!.B*=-?3>AK+0X.$%SS!"L]TY\+T M6@?MQN')^NR,S _YC/PUV1FK9Z;P32^Z^8N6&1+HQ MUS6,Q]3G_J,XN.(G9!AV2,%KQ8R*:9*!KK=J_;]3-\U^I9/1R.C M9WMVX'D6F&I>T!L/^@'M/2E:J7R_I_A^^VBV\*PS-&P (![G[=&-%GM%5A7'MSP;"L]YT6^<1YX8AI1H661: -" IQ&1EXF8B9()RV4O MGL3>2NF$_U)(H!EE67*9]B;LTB[1CO"[5/LJCJ17P7M2#'>1@+C*;S#GNIS& M 9^&]CNEW_E[SJ6Y=NVT_,\S_5MQW3Z ]=T//HD]TJ!^"D@_H)>@N\A^V">0)Z#Z<\R M6P&1I98&^/F++&/@YDD&4>25(L0S B^P^R/=MRU[3'LCTQPX/5!/0HF='%;H\GJB%_]:LXOEB%(78R4&T;,H.F8JO-B.X'L^NG:QS M=+3J1$[$>$FC\&C]RKF*&V$9'.:.(6)?/BJ[MBY3&M%F@?E+QV8P&@4F.D.N MY1F.9= 1-0:^;@^4:-LUT78:=RY3T-^U:AWL,,!MPA^0;&67) F8J#E(%Q-M&,Q"+-X4 =O"P?MR4!2GO^U$H@\3T?+K1C2W_@QQEEZ& M=HIIH]7*%R*"3D6%*!8;K2,#?QJW=NG<2ZN -,I[V#I><$/%TUF56BP2B; V M0!1RS8&,E)<(575.K&(!X\,YV]^BO "I7=MKF%BY9@R.L8)FK'PHSK=(\<3, MFU&1N$30/:"^E^5X3G:MS43"7K%ZM.*CF_7['HT[V6)<.-G=U=PGW&I1.=T8 M3BL*/HK"(N8IL(\OYJB563SOB@6J:T5N@I@L!;FW 8PL7_"@,++YS)I>Z#\WB1W 7Y^8L@P'L MLFB!,MQ;)QZNO!1#T2S 5S[2BT"ZQ.*\JT@:0-@7D0\:3\ #9OJ$1?2^)>D$ M[%Q0 7%$;YIR49SD8ZR/]0RI9%>M!I[%+E),>DJ+U@"@6+H77>T"$[>J4OO# M/WVPJ"=L^%G(HI"E5KDXW"_CAFP*8(Y'B1#QL$ D!.VPGGVPB'74:$9D"HGN M(3X MI8Z \GXP>"BZFBK/JK+8M,K2+": 62GH'=U\A%E8"X+P6(8XQ$5)5^6DK>_J MP.1S7#90BVG.$E]9;JU(WU+1@4=*E+$[\CS3<>U^8(\MM^&WP+S M2:GN2J*T5*+8'?B/LUZA/D2JU K1"QNL;A"N$RF5""GZ82&"EZ2%Z51=O4 < MS!)>WEZX>O C#VFB&%CZJJ6O?A7+;2@[8P'9PY)$,UH.%J%IF/&Q1JRWS&*. M(0H1V 3 +&9ST9MYU>0MO$X1E^2%\<)Z6[?\9MF8\+Y39F:"V6CK'>N2*:M3;0L&&-M?^9)3GE_&R^.%_!/0Z8N/6OY&3^! M;.D8M>W S__DP&L5G0G+-<,8"587U;LIK:- Q788VQ5!AWJRK6"J=LCOK?06 M6&GP^PC[MOD,7N7WHOV:GE%0E;._;%: KZ^VI"R7\H+.<][TTM)YUTOM&KL& M/T2@W?+T[5>;KTSZKKP!T4VHT=T#*-:$T!U%DNLY@7S566H\I@NZ4>3!LSWD*>+U>U<,%,A;=5#2CXSN,$2,:; MXK%$VH+NS;YGM;YTJ\=Q(N>ALA77B)P6@^V6QW^MR_?U6!&;S3:1M9HN&;"^ M^PU%@;Q:8]4[!S9$(R#QW8KH@AUO10G.)\!.K3$RDEH-!PMJE:;Q>8) M?7$&(_!&5,EXG-$\+YY0,2G%NIIZ^LDL_%,H==:"S*L"1KQ8L.!4'IYAW<>6 M*\:7VG4M%RNOTX5KMZ)8QK=&0T=R9T7RVGY?]W?Z ADTKMI5UL+IM9)CEC!;_N@=C\D!7J-$J,D]4JXXH"]7+C)8H]JM/H?2I;Y?&TNV/8)FR% M?3" L:$FX] B,E!*J_N-!9! 3[$5#+OK%C+R<7J;*?^?WNA=?? 6S6+47Q@A MQWJ\,%K@24]L=E,KS@3863U\.(Y8@ MS;0?_XH0JROZV:W*V.'+2PJ13:G:69B/52M=%Q8ITR\P!VQZQXK6F6>)_6^9 M)\(JQ*MS\X".%IKQ;>#D6"_2M-M\54[NCO6IAJ8BXL"7=*T@:N,XGJ#@F=5P1NS,)*L2O&S=&FC721%=?UL4!N:AG5F(=7RF-,*+]9('(K]&T^I#O9;P%-_NAZK.0E5$7 MD8&7B=:US-(53J%[#Y*!G2>3E$XPRL-:HEG=7OWAY=!S[X:-RYC+]],%#4JN M:F5?][5B?/F&D:-XC)R 3+U9V7[)^Z)G6>'7%M/ &DE,P5F^9:.\Z.3LFW9X M*78/!21N!F8Q8K%8AB*K,$K82!\6C]*>>Y\PJ%FJR,6GADCC[,1[+@7 .AWL M3;+ 67+>6\3AOQ=4.SLZ*?J^%^O#J634FV'7C^BFJQVQ]MGH!( H8MO5AAJV(]6\10"._S4=L< K=]&JU;,5%+V:O"LOC!CW\U2MXF* M*X9"?K#\.Q\H*WIE%Q6RK!T]+"@326NW1"U@'ADX,N0'-C#/Y]F[7WX)TRX( M?:^\FJ0+M/Z%T2_KB%5FM8T&.F#UHC]E%YH49%A9<461)+YKXDLB$3/C8*.0 M3\:Y\!_97)Y15-SB2&U(<@Q'V"RKZI)A#\SWRU'EQ^NXYQG.&Y! 273C1VAOD0<$V;IE*1#Z M0KR+>A78P\[JS;3N(> >#X(-EU?)HF%3W-E3]6:B7MDKN"C*@Z4D[%:-E>*\ MLR.\+"C*$NU[G%R+FUUJE7P@'*I/BQI=_-;!P5O1KJF\F\<+$A!E/L/[&\-$ M\63TF2W&[ ?PRFL+#K/:%4/E99N-%@-<501HD,8H-L,9K(#%GA>P&EC)C]SH44Z1\RB,<.EO@R!D&0%AL MCQ&/D8D6MS=Q7<6N.LKRJEF"T$R,NQH\PN981+LQ=:Q.AC/&#=D[, <,O4]< MO4?@Q[YA$W/ F\JX9& X9##H=;5]7F&A@?/.)Y:PUH!A9=QHWAKQI14=OJL; M(U?N0?$]=F\3NZ#H7A4 ^N/Z>E4+K13F/>>]52HX]_S!N6UH5A' _9 MYL7S M5E(D\/DL3P)K>3H%+8S&7U,7(>O':.IG5]+% M)&Y7TMHWKY&G__PJF@=EV 5\(^ $O%HH"F=A7@6VQDD4\20MY&]V](?!#N . ME*P,)" J_Z<#*_M.@Z(7+'R$.>P@DFCVF .,-L8F;8+T^MH9I_ M#[/O($ ZPRA(4<. H@Q "XJ&'NQ:+W8\,N*=QI:&JHA,"4!#OPN+7Y( /SLS?#)16^BZZFHY@JH[P4\\EMK=U)4;!4KP07B)6), M;"]7VJWSX@++J!M0\;/IXQQK>[@"^ LYZ MA5G"C["AV5OFWT4LF(NXK3:WJWVI<@57[.?FI(FX2 XD*J"WCEP1R5\#W><. MCOZQR+"SVT;PV[RWE]W7NZF@_@\O8^72>Y9=L)D+@A]_/W ![5I8M6X@-4V% MO-88)<>SK^_LZTU/DJF\Y@=$@?V:CF.9P)F !#:22 A.UX$?MW,M11XIF>FB25P6(*VIN 89>$'II<3DDBT^6%H?'A!?. ML@16,V8GE#(3"V7-(:F2L JM7+N$E%W:%B&4Q1@KB*R1L?A"0;CN4FM44<$8 M9DTY20LI61>1M\K'@H67=BNK^J%B& Y61,LFT_-D7E@"#S&7[I(60NS%HB"T M=L)1BJ-Z1]-U,T#C"DO4\?0-PZ&P%G8R%+$.JRO!998U@]\1W4?6/ 77Q+V9 MHO-S1T8CKP;L]IGN(?+E)@ M0U@)'U@[2;J:9?6QR2'!1$8\PV:Z!SVZJ&QS*^CL9?QN]B7V*2ZV9UF,/J;7 M!BR%8ZV1=;LY=:LCI!+[VA8[W+R-^H4GM7:.D^0[KSSW^!W?61LS3MAP[S0, M1(4^+]1@O9K8W9F4(>2[>J<5&>&7\EUOI4>1S$5;5CU-E M@<,R2>FF^BP_">(=#E'"YE6'$E+&,7$FX0P[B8P73!N6EV>!@F9RJG$3,Y99 MU&[M)$*SW!0[RD^-KA.\9=8KM[=6_EK>K"W>$K?8KKSN8Y>LY1?+:UQ6WF"% ML"LOEZU-EM_ ]+HX6'D9%K+\$O8W7OF:UY,_ULV#]_Q:?I6K_I4/8T+" MRFN-[^--N7@!%I8+^ZS+,O!2"&(3DYJ #5'Y5EO&-P,V#HB4TJHI;!%UG8$& MQ"OE1%SU=BARPZWD/PQ<8^2U&;PFC2^46"K-J2:7X3S*/,%2=6J,[XK/O.=X M7_!GH5S L3F\ZZH*BXKJX7R2\-@M6.?+3O")>)$>^62=V:^W-IK2OBFM6A4]4R8 MAP@( OYC6E1#T)3B;-XW"]0QYRX-;CLWK]9$N"IX&<5@$#(3N2B'0;&*UC(_ MU@C$93*!5EQ-W=2*P8+RS'2><<:M<]Q[U'OH=20I'@D4!;8<+$4!*:9;+5C+ MDRD8#453+M];B.O BVM>X$6&8Q&NCQ-6 )MZ_*9!<8?7[4*@(D ML7C=8EA> M%7/H1+F+A[D,,$P7&\30>:G) :JXG'IG&6!.;(>+IU21=\V)O(AH44@<)#1C M8H=Y(#G&F%'Q):.HT/ P]&(>L(XZ\Z4VGC5H#1\ >[;X=YD3^+SGI$>GB?AA>(>8\9* M5Q?,+CB\Y@UR-B7XU%MXDU&H*96%IL!2J)HB03,AK,Y*;R?%/>>;_/8TMGR1 M4UFG0 ,DN-9Q&+$+ OJ"99^B=_R;X MWW^PIPWP-Y;@!.OV,#63;QIY(E-A[^NUL>/(O;?_TY'*X?WE'J?/&4LDO MOL/XJ?896&"VCMS2L<'3RS\.+R]-S[?SP>'AY='IRL4VN^(9A M+# CM#.0XUX,]G=RAY^ZF7*XIU)T=<3;N.];<6]0Q8;#= ("#^MJ8]3#_]NL M"C,-L]/#YA"N;HKL9."^=75@M3HOO:CR^A'J+#[-Q);\EX=3FXN9<1Y?/+Y> M3+6#;U>TB9OJU4-M$__W3,+E0S@#Y9[Z'_? ]YY0G+/1_6,^6=X/<2IY='I\ M^O5H_X)H1R?[8#:?'&@7OWV^.#HX&IX?'5ZT;GD@*"].CX\.AI>',--+^.?; MXI$^LE-^P2&_'&>U^\'PLN;0669U##&;L#Q_%[(WCYQUMSW=N-JX'"QW77NF+C?MSC$FG,$ M/OZ[=ULT@7]\S5P%G4H)ALBOXJQK&V/=-X6*W)-%#MR$V[&')( ]@J\9>[=M M]4I[K6+6FYAD,9W>XVDFQ&8Q&[&K&JO$%G-K3NA^O#VJWKWL'H2'_]_@G6FF M':X69S^H?=)CMW0/S9*+$17E+[I/9) M[9/:)[5/Q=RVI"X?:N;P5;%7PC@ F^>=UNEWS=IY(7[BG29>^Q%KZ/SPGXO-N(2:086PD@M4]JG]0^J7W:785>G,([YL]KDUOV]P\/OWS9@-XW>@]2 M_'N?SD0-GKC1H\VZODQIN(>6S\2?6!N_B;#- U=Q%T?3%+$-HCLVL4U7H@C?RS*\@JF"Z;9A:NJD9]MD8,MTY*-@JF#Z MNF!JZ!9Q78,8AL*IPJG":5MQBA:O8Y*>9;T:F+; T5]_,+\U%_^8][62S<7? M:"+-2XBY^Y-:GFDQ+R&AGI:AG/))A:\5N%H++O!93=EYP.3TRVDZ:*,Q5GMI.FBC,59[X,3;=O K_HB=X3^OV+>YQ/OFJ' M_W-V>'+1\L[_*JF^E1+C)5;1QOQWA0)Y:*]0T):=4"A0*% H4"A0*-@]%&S? M\]IBS]5SFE$O]:>:%P=:0*]HE,QG,*XD'I5$0D(B2?#4BGVBVP9Q;3E3EEJL M+16WMY#;^WWL^Z)X7?'Z[O.Z21S+);9M*VY7W/X*N-TU^D3ORWEU3(O]G9;> M, E;,_,T'X:BJ9;,:>KE83S1Z)]SO)9"]?)4(97V=&ZRR< !3:SZ#2IDM9#V M,B/+(H;=(Z8I:7JW0I9"5DN199BD[SC$D;5EOH*6@E9+H34@AFN0@?MZS,'M M>[%;=%6'LP3F^Q?XITF,O3S#./?B23B*J 9[1G-9?%6)))!$8N:I:KH_( -+ MSH[ +5;$BM<5K[=SEQ2OOPI>=ZP><0QU=*=X7?&ZE+R^?9=G^YT@'^PB7< > MP4R)-J$Q3;V()3AZP2R,PRS'D[TKJ:\\V)6PCNI7L^E^-89)!JY%#&N'FN5* M&HI50%9 ?@*0==(W>Z3ORIEKJH"L@*R S!NZ$J>'&GF'[H900%9 ?GU -HCA M#LA@(.FQZW-Q?TL#$^VZA^(RR;U(XK1B=<..3$+OJ;[&@+A]BUA].4.HZOHJ M!:X6@\LF ],DMKIX48%+@>NY[X:SB>7:I&?L4+A;@4N!JQ7@LDTRL %@K^)6 MTQ9XM7(&U78D?K8;T;'7V=-+H4 >VBL4M&4G% H4"A0*% H4"G8/!2WP9E[F MC.X)-TL1Y&$7 M32J@*J"^*% -F]@6-A'((VDUN$*J0NHK0:KM$&-@ M2MMT?7M(;4$,0,7O5/Q.Q>\4"A0*% H4"A0*% H4"A0*% JD/-%LU>'EZ>6O MA^?:T[?2^U#:ZH MZ$\IB2\JD;212*0\-5/7(]??>PG8>8QTF6:4D,CB/> M;[ (L^D,1L7KZ0,ZRB612BJ@U1Y9MKF 5D=*Z:9"Q I1"E&R[:I"E$+4CR#J M38_T>BYQ=_'@Y54XN JFKP&FKT?QM<#O?9D.H@_V>$_S*4TE.RA5O9):)98V MWRBT)ZL!H1J:*9"^"I : ^+8WSA6W+12V'\MI\:&-1/)'(A$B?S=!Q9F*,Q5G*LY4 MG*DXL]U45)PI16_@9<_ ?NGCS"=<_W%R>*D=GUYVDXJ*,S=V_/M:CWL_#R^. M]K7AR8%V<'3\V^7A 3O\U2 ]_?#HZ^_XKGN\)^' MY\.OAXUCW0OM]+?+B\OAR<'1R==WLH0R=B1JL1O]PS:_BC;>8:90( _M%0K: MLA,*!0H%"@4*!0H%NX>"[1]"K#V;V=JMKNNS;;TL]#4O#K2#,%KD-)#%Y5I/ M6HE$R[VGG5*)F >LYDGGCH;;(]; (J[E[,XQ;9L5N,+7Z\*799%^7R>&O4-) M5@I?"E]MP1?H+U/'9GP[E"*M\*7PU19\F0[I#4QBZ_HKP->2:UO\!"][0,_R MG14*UF:Y]^G#J!JC2;/Z]_R(>BF;\;1T._-D7JQ5O%+,F@]=T.WS^=F7,V]" M/Z?4^SZ$_]0WN?Z0.7RH,\)/=;PQ2()WFA==>S?9+4,U>>7#-(6-RZ9>0''G MV _EYO#Y,7)J.F9&%B37]8HMQ6OZ>VTJO&-VM\_(_A+.)EJ7^Q[UP!D3$.1O=/^:3Y?WX M-#SX-M0^'YT>GWX]VK\@VM')?I?5XE[\]OGBZ.!H>'YT>-&ZY>V?GAP78OH*[3#T960"W#U?N6[>\]4-RM M4F55Y"QS:)WO]];(#KZX'PF0K1&)#PZ6W74;>LMLB\U-M9B4^7CZ+>E5F).X M*"N=C-[H1,/_OWU$R+& Z8^$$B_H/*>S$4TU2R?KE/!F'JN9NBG3!>N*Y7>' MY0^H+SC>>$&.!X:7Z8*Z'^"B[1S=M"I+;GAQL6*T/-,V/Y-X>*K_^>,RX-G! MO??IS6^QMPC"G :;J9_<"+3:%G_9)D>T^2"[94?4VY)SX*@MTA1&T8#:-,]: MG=ZK>%G)G)WQ'"DF'([HIZ:E)"Y-C%7(5!.'FFI=2G8)J,(DJTF.;R6B<2"3*)4BN>*$9,'0P MDU@#.=-JY=+R"@%M1," ./T>&3AR)KZV++;8?K__*+Z"49(TI,K3;[._((W\ MV9R-;_1,XAH6Z5F2)@TK]US!32*XF3;IPU_=E2F]0N8B668EK,\/V9I]<);2 MN1<&&OUS3N,,WL4S@B2?TE3S&\>7$EL/=Z7D2"'(UI<3\#RP9UW,]FHCZHMY M6J206'V3V(,=Z6_\K-NKX*;@]LQPLXEEN<2TY0RH/8Y76V ]O&2,P70>:$-< M)KD7[8ZYH+R?%HFO37D_)O-\;.)(54VA@@T*;G+"31^0OND2RU#!AD2Y1^Y2"E][:])$ER'422O"2"1Z)%(OCRU6(XXIDL< MW952B,BEEA4 % "46[U5M_H\Q\G5B60P9]E2^O MT";%=LB,MCXQ>R;I.( MZ9C8#^%UBXKM6W%R23&)I))$CEF[>XVK+ /%K#O%K-L7^K)XZ<='P\]'QT>7 M1X<7_)[(R]/]__[U]/C@\/SB/[7#?_QV=/DOB;WW';&^=_X<4Q*!LSN^J@*& M L:K/XS?_D5:4>B-PBC,0]J2V[24&=X:N2 -^.52?8I9%;.V4QVUL]]Z>9') MW+O!6TSD55.OP.A]I0&T8B<2>5]_(T83,@5G] 7$O.+'2Y; &%@#8BH$], MPR;N0,Y:LA;KU'8&!8KX]3R!%26QEHRU@(XIO!AH*;VB\4+%"=KL;4@CES;H M(=@F&5B29D**'KTGLE*L:V%:) ML0W7P/9-G?2=UW ]E *; MN6P>:X!M%?Q=6'+3 :)+B+;2>"^,KK:9,$VY37 M8]O$MG5BF7TYI9>*,2BTR8,V2V=G<)8AJ6$N99AA>PGT%S0.DQ36DM,R,Y%= M&\..(L*,Y2S*:R%())@DDCY/#F,:Q.HYI"]I.J!<:EM!H(40<&TRZ/6(:E+*K64)Z[ )A78 MW+X#@%..^",7*:4C?HAY]F,8,)UI8RIQUI]$$D@B,?-D6>+H.M%U.?N=RJ6= M%0!:"(#.;C'^]C5E*_WLX^5<..5HMU/P*-O_W@O<>E:/Z -U@9M"FQ3;(3/: M^L3NF<22M.A.3D^[91>XG;(2]SB).[N5(:>2?-LDP#:[,OM&N^(H;P; M9O#KO E* 4/J[5# V-WC;KDP*Q$P)4*?-!!3S-IVPBIF52[9\[EDZK+J]HD* M97"V1< H3TP!0P%CASRQ;>48GZ5%&Y"+//&_$^TGO:OKNJ'-O117C'U!#%:E M2=BA[=1+\0*N13Y-4EA+0( ,Q:MAEN$U7>QVKD6>Y?!#&$_D5=H2"2")I(PJ MFE2,WT+"*L:7PA/>+<]W[].'T?*JD32R:DQES;='W+Q6:UX!0^KM4,!HF9LK MI5N[G\QF2*)KG5M+O].[-=P>Z?=[9- WF&-KN X9&!;\[2NW M=^L"22*I\]1,=I?T^G(FLM=("'01!B]RLO JT< M!C"HYGOS,/36HLO;;(WDV5USF]'K$L%TRL.6\,D(YUPIN,L'-L8@I\0TM MA5P[T&B8QX&_?E#,.L3WTMM2(:6$TY(Y673N6#J_:^LCOZ&VQ MK8^N$PLL*<>2U!54/;L4N!6X;[^)U^B;Q.F]5@?4]:^9<>- M)7LW',T@68PB^@">NE=D_+21S=V>F'T^RF!VD^/TB=.7\Y:US?*^@J^";ZOA M:_9[Q'0PZ+0CS8GOY/TE@Z?X"5[V@)[E.RL4K,VR65#1I-EFOE?-]\,4+VO) MIEY D=;LASU-[(4/Y@]-2^I.A1G#;,/"(.3LL]96+-ZJ;P(?&UL4$L! A0# M% @ #X)I5:JY%/_>!0 _#X !4 ( !+ P &%D;6$M M,C R,C$Q,#E?<')E+GAM;%!+ 0(4 Q0 ( ^":57>"-T,6Q( (9S 3 M " 3T2 !B#DY+3$N:'1M4$L%!@ % 4 2P$ '5< $! end